Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Bio-IT World December 15, 2004 David A. Bumcrot	Identifying RNAi Drug Candidates Breakthroughs in understanding RNA's extensive role in essential cellular processes have opened up the potential for a whole new class of drugs based on RNAi.
Bio-IT World July 15, 2003 Malorye Branca	Silence Is Golden RNA interference's scientific, therapeutic, and economic potential is unquestionable, but some sticky questions still remain.
The Motley Fool February 9, 2006 Jason Mac Gurn	RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals...
Bio-IT World December 15, 2004 Samarsky & Welch	An Unusual Path for RNAi Technology Traditionally, development of novel technologies and research tools follow the basic scientific discoveries.
Bio-IT World November 2005 Robert M. Frederickson	Innovations in Interference RNAi has moved from phenomenon to promising drug in less than five years, but it also has potential to be a tool used in drug discovery.
Bio-IT World December 15, 2004 Zachary Zimmerman	Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies.
Bio-IT World December 15, 2004 Nancy Weil	Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic.
Bio-IT World November 2005 Nancy Weil	Dharmacon, Institutes Form siRNA Global Initiative The company has formed a global alliance with leading biomedical research centers aimed at speeding scientific and medical discoveries now that the first complete siRNA (small interfering RNA) library is available for targeting genes in the human genome.
Chemistry World July 17, 2012 Simon Perks	Synthetic nanozymes silence hepatitis C Researchers at the University of Florida, US, have discovered that an artificial nanoparticle complex, known as a nanozyme, can help to treat viral infections by 'shutting off' their genetic material.
Chemistry World October 2, 2006 Bea Perks	RNAi Pioneers Win Nobel Prize for Medicine Molecular biologists Andrew Fire and Craig Mello have been awarded this year's Nobel prize in physiology or medicine for their discovery of RNA interference.
HHMI Bulletin Winter 2013 Sarah C.P. Williams	Cellular Search Engine Craig Mello's lab has now uncovered the reason piRNA molecules are so ubiquitous and exist in so many forms in C. elegans: so they can pair with essentially any genetic sequence they encounter during their endless scanning.
Bio-IT World July 2005 David M. Evans	Cellular Imaging Takes Drug Discovery to New Heights The potential applications and ultimate value of high-content screening (HCS) and cellular image analysis are limited only by the imagination and expertise of the drug discovery groups using them to probe gene function and cell behavior.
Chemistry World April 28, 2008 Victoria Gill	Gene silencing gets fat A team of researchers in the US has developed fat-like nanoparticles that can carry fragments of RNA into cells, bring treatments based on gene silencing a step closer.
Bio-IT World December 15, 2003 Malorye A. Branca	Scenes from a Cell Breakthroughs are making cell-based screening faster, easier, more powerful.
Bio-IT World November 12, 2002 James Golden	The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success.
Bio-IT World April 15, 2003 Malorye Branca	Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease?
Bio-IT World October 10, 2003 Donna Mendrick	Microarrays That Make Drugs Safe Using DNA chips to discover potential toxicity in new drug compounds -- a key application of toxicogenomics -- can predict adverse effects before they occur, enabling safer clinical trials.
Managed Care November 2003 Thomas Morrow	Making Sense of Antisense and Interference Treatments that interfere with protein synthesis at the cellular level will soon be debated in medical policy committee meetings.
IEEE Spectrum March 2011 Lucks & Arkin	Synthetic Biology's Hunt for the Genetic Transistor How genetic circuits will unlock the true potential of bioengineering
Bio-IT World December 10, 2002 Rotem Sorek	Alternative Splicing: Listen to the Mouse The completed mouse genome may help to finally pin down the size of the transcriptome.
Bio-IT World Jul/Aug 2006 Deb Janssen	Managing the Microarray Data Mountain Genomic studies often involve thousands of samples and require hundreds of thousands of assays per sample. Microarray manufacturers are scurrying to satisfy researcher demands for increased array density, sample number, and content flexibility.
Chemistry World April 20, 2009 James Urquhart	New method reveals small molecule-RNA conjugates US scientists using novel chemical screening methods have discovered a new class of small molecules connected to RNA, suggesting that cellular RNA may be more chemically diverse than previously thought.
The Motley Fool October 5, 2006 Ralph Casale	RNAi: Nobel Prize-Winning Biotechnology While drugs based on RNAi knockdown technology may have the potential to become the next big thing in biotechnology, they are still a long way from becoming FDA-approved marketable entities. But it's never too soon to start keeping an eye on the future. Investors, take note.
Chemistry World January 20, 2011 Hayley Birch	Programmable RNA promising for bio-compatible therapies Programmable nanostructures based on ribonucleic acid could be used as vessels for shipping therapeutic molecules into cells, according to US scientists.
Chemistry World January 25, 2010 Hayley Birch	Stabilising RNAs enhances gene silencing in tumours South Korean scientists have found a way to stabilise therapeutic RNA molecules, using chemical modifications, so that they can be more smoothly trafficked into cells.
Chemistry World January 31, 2008 John Bonner	RNAi Scores Victory Against Crohn's Disease in Mice Thousands of people suffering from the debilitating gut condition Crohn's disease could experience relief from their symptoms through a technique that blocks production of a key protein in the inflammation process.
Bio-IT World September 2006 Robert M. Frederickson	Assays and Knowledgebases for Genomic Analysis An important aspect of any genomic analysis -- whether expression profiling or analysis of DNA-binding elements as above -- is the integration of the data with existing knowledge.
The Motley Fool August 15, 2006 Ralph Casale	Sirna Battles Genes Gone Bad Pharmaceutical start-up Sirna Therapeutics tests drugs to silence rogue genes. Investors, while drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities.
Industrial Physicist Jennifer Ouellette	Bioinformatics moves into the mainstream An explosion of data is being tamed with new systems
Bio-IT World August 15, 2005 Robert M. Frederickson	What's 'Post' About Postgenomic? Bioinformatics tools can help organize and study genomic sequences that were discovered in the '90s. The tools help with tasks like analyzing gene expression, predicting protein structure and function, and establishing networks of interacting protein in cells.
The Motley Fool September 10, 2007 Brian Orelli	Double Your RNA Pleasure Alnylam and ISIS join together to work on microRNAs. Their joint venture, called Regulus Therapeutics, combines their intellectual property in an effort to advance this new technology. Investors should take note.
Chemistry World July 2010 Hayley Birch	Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade.
Bio-IT World July 11, 2002 Malorye Branca	Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed.
Bio-IT World September 2006 John A. Wass	Integrating Knowledge The results of new mathematical routines have the potential to save pharmaceuticals millions of dollars in drug development. And yet the flow of successful drugs is dwindling. The problem goes beyond bureaucracy and lies in the complexity of the problem.
Salon.com May 1, 2000 Arthur Allen	Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic.
Chemistry World March 21, 2010 Simon Hadlington	Nanoparticles successfully deliver RNA interference in cancer patients The system aims to exploit the phenomenon of RNA interference, where short sequences of double-stranded RNA, called small interfering RNA or siRNA, can trigger the disruption of the manufacture of certain proteins in a cell.
The Motley Fool September 28, 2007 Brian Orelli	RNAi Doesn't Kill Mice After All From Merck, to AstraZeneca, to Novartis, big pharma continues to pump hundreds of millions of dollars into unproven RNAi technology. Investors, take note.
Bio-IT World March 2007 Kevin Davies	Leading by Example At Cambridge Healthtech Institute's annual Pharmaceutical and Biotech Leader's Summit, drug industry executives provided accounts of the profound organizational and technological changes that are helping organizations overcome industry-wide challenges.
The Motley Fool November 13, 2006 Jack Uldrich	Arrowhead: A Long-Term RNAi Play? Its majority stake in Calando Pharmaceuticals could pay dividends. Investors would be wise to continue to watch this company and wait until clinical trials have advanced to a more mature stage before considering an investment.
Bio-IT World July 2005 Kevin Davies	Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference.
Chemistry World November 5, 2007 Lewis Brindley	Silencing the Pests Two teams of scientists have uncovered a new way to protect crops from two serious insect pests. The teams made use of a process called RNA interference to silence critical genes in the bodies of the insect larvae and stopped them growing.
Scientific American June 2005 JR Minkel	RNA to the Rescue The spectacular discovery that a species of plant can summon up genes its parents have lost highlights biologists' increasing recognition of RNA as a more versatile and important molecule in its own right.
Pharmaceutical Executive July 30, 2007	Tomorrow's Drugs A look at the seven top therapies and technologies vying to deliver the next generation of drugs.
Chemistry World November 27, 2007 James Mitchell Crow	A Flare for Gene Silencing US scientists have developed nanoparticle probes coated with DNA that release fluorescent 'flares' when they silence genes inside cells.
Bio-IT World May 2006 Kevin Davies	Interpreting Genes and Genomes From microarrays to sequencing technology, molecular diagnostics to the interactome, this year's Bio-IT World Conference showcased exciting advances in genome technology applications, in which software analysis and data management play critical roles.
The Motley Fool November 6, 2006 Ralph Casale	Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam.
The Motley Fool November 30, 2010 Brian Orelli	RNAi Is On Sale The novel technology looks more promising at these prices.
Bio-IT World November 19, 2004 Kevin Davies	The Book on Bioinformatics Research director David Mount talks about his new book "Bioinformatics: Sequence and Genome Analysis," sequence analysis, and teaching bioinformatics
Chemistry World May 17, 2006 Bea Perks	Biochemists Reveal Hidden Drug Effects Researchers have identified unexpected drug activities by probing biochemical pathways inside living cells.
HHMI Bulletin February 2011 Mitzi Baker	When Worlds Collide The right time and place led to a new RNAi-like pathway in bacteria for biochemist Jennifer Doudna and geobiologist Jill Banfield.